Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease

NCT07372989

Status	RECRUITING
Phase	Phase 1
Sponsor	Maule Stem Cell Research Institute, Inc.
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (8)

- In order to participate in this study, a patient MUST:
- Provide written informed consent.
- Subjects age \> 40 and \< 90 years at the time of signing the Informed Consent Form.
- Have a clinical diagnosis of ILD prior to screening in accordance with the guidelines of the American Thoracic Society/European Respiratory Society.
- FVC e 45% predicted and DLCO e30% (corrected for hemoglobin but not alveolar volume).

... and 3 more (see full listing online)

Exclusion (18)

- In order to participate in this study, a patient MUST NOT:
- CT and/or surgical lung biopsy results inconsistent with the diagnosis of IPF.
- Inability to perform any of the assessments required for endpoint analysis (report safety or tolerability concerns, perform PFTs or CT, undergo blood draws, read and respond to questionnaires.)
- Currently receiving (or received within four weeks of screening) any medication, treatment, or experimental agents for the treatment of ILD, except for patients receiving non-drug therapies will include oxygen saturation therapy (oxygen supplementation) and pulmonary rehabilitation.
- Active listing (or expected future listing) for transplant of any organ.

... and 13 more (see full listing online)

Locations (1 total)

Maule Stem Cell Research Institute, Venice, Florida, United States